title: Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry.
abstract: BACKGROUND
  Residual disease (RD) is an important prognostic factor in acute lymphoblastic leukemia (ALL). Flow cytometry (FC)-based RD detection is easy to perform, but interpretation requires expert analysis due to individual differences among patients.
  
  
  METHODS
  We focused at the design of standardized and reproducible RD monitoring in ALL. RD was investigated by a uniform gating strategy, which was designed internationally and tested in one center by Ig/TCR rearrangements.
  
  
  RESULTS
  For each gate, positivity cutoff value was assigned using quantification of non-leukemic background. Comparing to Ig/TCR at 0.1% level, 80 of 103 specimens were correctly diagnosed by FC. The predictive value of FC RD at day 15 was then analyzed. In B lineage ALL, day 15 FC significantly correlated with Ig/TCR results at day 33 and/or week 12 (P < 0.01). No significant correlation was found in T lineage ALL.
  
  
  CONCLUSIONS
  Thus, FC with preset uniform gating at day 15 predicts PCR-detectable MRD in B precursor ALL. Presented data may be used to define new polychromatic cytometric diagnostics of MRD including semiautomatic assessment. Pediatr Blood Cancer 2010; 54:62-70. (c) 2009 Wiley-Liss, Inc.
authors.affiliation: CLIP-Childhood Leukemia Investigation Prague, Prague, Czech Republic.
authors.forename: Ester
authors.initials: E
authors.lastname: Mejstríková
authors.forename: Eva
authors.initials: E
authors.lastname: Fronková
authors.forename: Tomás
authors.initials: T
authors.lastname: Kalina
authors.forename: Marek
authors.initials: M
authors.lastname: Omelka
authors.forename: Drago
authors.initials: D
authors.lastname: Batinić
authors.forename: Klara
authors.initials: K
authors.lastname: Dubravcić
authors.forename: Klára
authors.initials: K
authors.lastname: Pospísilová
authors.forename: Martina
authors.initials: M
authors.lastname: Vásková
authors.forename: Drorit
authors.initials: D
authors.lastname: Luria
authors.forename: Suk Hang
authors.initials: SH
authors.lastname: Cheng
authors.forename: Margaret
authors.initials: M
authors.lastname: Ng
authors.forename: Yonna
authors.initials: Y
authors.lastname: Leung
authors.forename: Janos
authors.initials: J
authors.lastname: Kappelmayer
authors.forename: Flora
authors.initials: F
authors.lastname: Kiss
authors.forename: Shai
authors.initials: S
authors.lastname: Izraeli
authors.forename: Batia
authors.initials: B
authors.lastname: Stark
authors.forename: Martin
authors.initials: M
authors.lastname: Schrappe
authors.forename: Jan
authors.initials: J
authors.lastname: Trka
authors.forename: Jan
authors.initials: J
authors.lastname: Starý
authors.forename: Ondrej
authors.initials: O
authors.lastname: Hrusák
mesh_terms: D002648:Child; D005260:Female; D005434:Flow Cytometry; D015321:Gene Rearrangement; D006801:Humans; D008297:Male; D018365:Neoplasm, Residual / Q000175:diagnosis* / Q000235:genetics; D016133:Polymerase Chain Reaction; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis* / Q000235:genetics; D011379:Prognosis; D011948:Receptors, Antigen, T-Cell / Q000235:genetics; D012074:Remission Induction
chemical_list: D011948:Receptors, Antigen, T-Cell